Literature DB >> 28129499

Toward National Estimates of Effectiveness of Treatment for Substance Use.

Carlos Blanco1, Aimee N Campbell2, Melanie M Wall2,3, Mark Olfson4,2, Shuai Wang2, Edward V Nunes2.   

Abstract

OBJECTIVE: To estimate how results would have varied if a substance abuse clinical trial had been conducted with nationally representative adults with substance use and with representative adults receiving substance use treatment.
METHODS: Results were analyzed from a multisite clinical trial comparing the effectiveness of the Therapeutic Education System to treatment as usual for outpatient addiction treatment (n = 507). Patients were recruited between June 2010 and August 2011. Abstinence was the primary outcome. The general population sample and general population-treated samples were derived from Wave 1 of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) (n = 43,093). Propensity scores provided a standardized measure of the difference between clinical trial participants and the 2 NESARC samples. The clinical trial was reanalyzed by reweighting the sample with propensity scores derived from the 2 samples to obtain generalizable estimates of treatment effects.
RESULTS: Before the clinical trial sample was reweighted, the odds ratio (OR) of response to Therapeutic Education System versus treatment as usual in the trial was 1.62 (95% CI, 1.12-2.35). After the sample was reweighted to be representative of the 2 NESARC groups, ORs were 1.33 (95% CI, 0.34-5.26) for the representative sample with any substance use and 1.64 (95% CI, 0.82-3.27) for the representative treated sample.
CONCLUSIONS: Applying propensity score weighting to clinical trial results provides a method for estimating the population generalizability of clinical trial findings that relies on effect moderators observed in the study sample and population. Broader confidence intervals in the reweighted samples do not necessarily indicate lack of efficacy of the Therapeutic Education System but rather greater uncertainty concerning effectiveness in general population samples. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28129499      PMCID: PMC5490656          DOI: 10.4088/JCP.15m10333

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  39 in total

1.  Probability and predictors of treatment-seeking for substance use disorders in the U.S.

Authors:  Carlos Blanco; Miren Iza; Jorge Mario Rodríguez-Fernández; Enrique Baca-García; Shuai Wang; Mark Olfson
Journal:  Drug Alcohol Depend       Date:  2015-02-09       Impact factor: 4.492

2.  Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis.

Authors:  J M Pogue; S Yusuf
Journal:  Control Clin Trials       Date:  1997-12

Review 3.  WHO Study on the reliability and validity of the alcohol and drug use disorder instruments: overview of methods and results.

Authors:  B Ustün; W Compton; D Mager; T Babor; O Baiyewu; S Chatterji; L Cottler; A Göğüş; V Mavreas; L Peters; C Pull; J Saunders; R Smeets; M R Stipec; R Vrasti; D Hasin; R Room; W Van den Brink; D Regier; J Blaine; B F Grant; N Sartorius
Journal:  Drug Alcohol Depend       Date:  1997-09-25       Impact factor: 4.492

4.  Generalizability of pharmacological and psychotherapy clinical trial results for borderline personality disorder to community samples.

Authors:  Nicolas Hoertel; Saioa López; Shuai Wang; Ana González-Pinto; Frédéric Limosin; Carlos Blanco
Journal:  Personal Disord       Date:  2015-01

5.  Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.

Authors:  Arif Khan; Amy E Brodhead; Russell L Kolts; Walter A Brown
Journal:  J Psychiatr Res       Date:  2005-03       Impact factor: 4.791

6.  The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample.

Authors:  Bridget F Grant; Deborah A Dawson; Frederick S Stinson; Patricia S Chou; Ward Kay; Roger Pickering
Journal:  Drug Alcohol Depend       Date:  2003-07-20       Impact factor: 4.492

7.  Assessing the generalizability of randomized trial results to target populations.

Authors:  Elizabeth A Stuart; Catherine P Bradshaw; Philip J Leaf
Journal:  Prev Sci       Date:  2015-04

8.  Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report.

Authors:  Stephen R Wisniewski; A John Rush; Andrew A Nierenberg; Bradley N Gaynes; Diane Warden; James F Luther; Patrick J McGrath; Philip W Lavori; Michael E Thase; Maurizio Fava; Madhukar H Trivedi
Journal:  Am J Psychiatry       Date:  2009-04-01       Impact factor: 18.112

9.  Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Carlos Blanco; Mark Olfson; Renee D Goodwin; Elizabeth Ogburn; Michael R Liebowitz; Edward V Nunes; Deborah S Hasin
Journal:  J Clin Psychiatry       Date:  2008-08       Impact factor: 4.384

10.  Policy: NIH plans to enhance reproducibility.

Authors:  Francis S Collins; Lawrence A Tabak
Journal:  Nature       Date:  2014-01-30       Impact factor: 49.962

View more
  3 in total

Review 1.  Data needs and models for the opioid epidemic.

Authors:  Carlos Blanco; Melanie M Wall; Mark Olfson
Journal:  Mol Psychiatry       Date:  2021-10-29       Impact factor: 13.437

2.  Under-representation of key demographic groups in opioid use disorder trials.

Authors:  Kara E Rudolph; Matthew Russell; Sean X Luo; John Rotrosen; Edward V Nunes
Journal:  Drug Alcohol Depend Rep       Date:  2022-07-30

3.  The relationship of frequency of cocaine use to substance and psychiatric disorders in the U.S. general population.

Authors:  Efrat Aharonovich; Jennifer Scodes; Melanie M Wall; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2021-07-27       Impact factor: 4.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.